RBL 001/RBL 002

Drug Profile

RBL 001/RBL 002

Alternative Names: MERIT; RB0001; RB_0001; RBL-001/RBL-002; RBL-002/RBL-001

Latest Information Update: 24 Jul 2016

Price : $50

At a glance

  • Originator BioNTech; Ribological
  • Developer Ribological
  • Class Cancer vaccines; RNA vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma

Most Recent Events

  • 24 Jul 2016 Phase I development is ongoing in Germany and Austria for Malignant melanoma (Late-stage disease)(Intralymphatic, Injection) (NCT02035956)
  • 01 Jul 2015 BioNTech completes a phase I trial in in Malignant melanoma in Austria (NCT01684241)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top